BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung
14 janv. 2025 06h45 HE
|
BioNTech SE
BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
14 janv. 2025 06h45 HE
|
BioNTech SE
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
07 janv. 2025 10h52 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14.
QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery with first successful simultaneous 10-target multiplex-screening
07 janv. 2025 08h30 HE
|
QUANTRO Therapeutics GmbH
QUANTRO’s proprietary time-resolved functional transcriptomic discovery platform accelerates target screening for complex indications in oncology and inflammationQUANTRO CEO Dr. Michael Bauer to...
Kailera Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 08h15 HE
|
Kailera Therapeutics, Inc.
Ron Renaud, Kailera's President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025.
Artios Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
19 déc. 2024 08h00 HE
|
Artios Pharma
CAMBRIDGE, United Kingdom and NEW YORK, December 19, 2024 – Artios Pharma Limited (“Artios”), a clinical-stage biotech company led by pioneers of DNA damage response (“DDR”) drug development, today...
invIOs to present progress across oncology pipeline during JP Morgan Week 2025
16 déc. 2024 09h00 HE
|
invIOs GmbH
VIENNA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- invIOs GmbH (“invIOs”), a privately held biotechnology company developing novel therapies for cancer, will be participating in JP Morgan week activities in...
CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week
12 déc. 2024 07h00 HE
|
CytoSorbents
CytoSorbents Is Scheduling In-Person Investor Meetings During the JP Morgan Healthcare Conference from Jan 13-15, 2025 in San Francisco.
Inaugural Pre-JPM Partnering Week to Wrap Up 2024, Prepare for 2025
29 août 2024 07h30 HE
|
Big4Bio
New life science partnering conference to debut that prepares and helps industry dealmakers and stakeholders for the JP Morgan Healthcare Conference week
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
09 janv. 2024 06h45 HE
|
BioNTech SE
Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion (unaudited) in cash, cash...